Continued treatment of inflammatory bowel disease with thiopurines during pregnancy does not appear to increase the risk of congenital abnormalities, data from the large CESAME cohort has indicated.
CESAME enrolled about 19,500 French IBD patients between 2004 and 2007. There were 204 women who volunteered information on 215 pregnancies during this time.
They resulted in 142 newborns, reflecting a 35% loss from spontaneous and induced abortions that was comparable to the rate in the general population.
The pregnancies consisted of 86 which were exposed to thiopurines (usually for the entire pregnancy), 84 treated with other medications, and 45 not exposed to any treatment.
Two congenital abnormalities occurred in the thiopurine group, four among women taking other treatment, and none in...
This site is intended for Registered Medical Practitioners.
To make the most of Gastroenterology Update, you need to be logged in.